1.4, the fifth sentence, which previously read: “Enrollment

of 54 patients was completed…” has now been corrected as follows: “Enrollment of 45 patients was completed…” Page 272: In the third paragraph of section 1.1.5, the first sentence, which previously read: “…compare the efficacy of tasocitinib with methotrexate…” has now been corrected as follows: “…compare the efficacy of two doses of tofacitinib with methotrexate…” Page 273: In the left column, third paragraph, the first sentence, which previously read: “…efficacy and safety of tasocitinib in 2500 patients… has now been corrected as follows: “…efficacy and safety of tofacitinib in 4000 patients…” Page 274: In the first paragraph of section 2.2.2, the first sentence, which previously read: “…were PRI-724 in vivo low in the phase II/III ORAL Solo trial…” has now been corrected as follows: “…were low in the phase III ORAL Solo trial…” Page 275: In the left column, second paragraph, the first sentence, which previously read: “No new safety signals have emerged in the ongoing ORAL Sequel phase II/III 2-year extension study…” has now been corrected as follows: “No new safety signals have emerged over 2 years in the ongoing ORAL Sequel phase II/III extension study…” Page 275: In the right column, second paragraph, the first sentence, which previously

read: “In a 1-year extension study that included patients…” has selleck now been corrected as follows: “After 1 year of an extension study that included patients…” Page 275: In the right column, third paragraph, the first sentence, which previously read: “…at learn more dosages of 2–20 mg/day,…” has now been corrected as follows: “…at doses of 1–10 mg twice daily,…” Page 277: In the fifth paragraph of section 2.4.1, the first sentence, which previously read: “Cynomolgus monkeys receiving tasocitinib had a significantly longer…” has now been corrected as follows:

“Cynomolgus monkeys receiving tofacitinib following bilateral nephrectomy and allogeneic renal transplant had a significantly longer…” Page 278: In the right column, lines 1 and 2, which previously PFKL read: “…twice daily groups at 6 months, compared with the placebo group.” has now been corrected as follows: “…twice daily groups at 3 months, compared with the placebo group.” Page 281: In the left column, second paragraph, which previously read: “…significantly improved pain and physical function at 6 weeks…” has now been corrected as follows: “…significantly improved ACR response rates at 6 weeks…” Page 281: In the right column, the second paragraph starting with “One-year efficacy data…” should be deleted entirely. Page 281: In the right column, third paragraph, the first sentence, which previously read: “Tasocitinib, at dosages of 2–20 mg/day, was effective…” has now been corrected as follows: “Tofacitinib, at doses of 1–10 mg twice daily, was effective…” Note All online versions of this article have been updated to reflect these corrections.